STOK - Company ID 0001623526
The table below shows Stoke Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.23M | $10.63M | $13.82M | $158.57M | $4.89M | $4.83M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $39.67M | $37.70M | $25.86M | $32.68M | $22.20M | $21.14M |
Stoke Therapeutics, Inc. reported annual revenue of $184.42M for fiscal year 2025. That is up 404.5% from $36.55M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $19.97M |
| $16.03M |
| $15.26M |
| $14.65M |
| $12.69M |
| $13.04M |
| Operating income | -$53.42M | -$43.09M | -$27.30M | $111.24M | -$30.00M | -$29.34M |
| Income tax | $0.00 | -$1.28M | $0.00 | $1.28M | $0.00 | $0.00 |
| Net income | -$50.00M | -$38.35M | -$23.48M | $112.88M | -$26.43M | -$25.70M |
| EPS (diluted) | -$0.79 | -$0.65 | -$0.40 | $1.90 | -$0.47 | -$0.46 |